Voloridge Investment Management
AIMT

Voloridge Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

Voloridge Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-32,749
Closed -$682K – 1277
2019
Q2 		$682K Buy
+32,749
New +$674K 0.02% 521

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's AIMT Position: Q3 2019 in Review

Voloridge Investment Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 32,749 shares — an estimated $682K sold.

Voloridge Investment Management first reported a position in AIMT in Q2 2019 and held it in 1 quarter. The position peaked at $682K in Q2 2019. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Voloridge Investment Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Voloridge Investment Management sold 32,749 Aimmune Therapeutics shares in Q3 2019, an estimated $682K.
  • Voloridge Investment Management first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 1 quarter.
  • Voloridge Investment Management's Aimmune Therapeutics position peaked at $682K in Q2 2019.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Voloridge Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.